Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thyrocare TechnologiesBOM:539871 -0.74%87 Pretax Margin % is 28.45% as of Jun. 2026, which is 3% below its 10-year median of 29.42. GuruFocus rates BOM:539871 with a GF Score™ of 87/100 and a GF Value™ of ₹416.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 94.53% on this metric.
The historical rank and industry rank for Thyrocare Technologies's Pretax Margin % or its related term are showing as below:
BOM:539871'
s Pretax Margin % Range Over the Past 10 Years
Min: 16.9 Med: 29.42 Max: 41.37
Current: 26.33
BOM:539871's Pretax Margin % is ranked better than 94.53% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.57
vs BOM:539871: 26.33
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Thyrocare Technologies Pretax Margin % Related Terms
Thyrocare Technologies Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539871 vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies (BOM:539871) has a Pretax Margin % of 28.45% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Thyrocare Technologies and its competitors. This is near median its historical median of 29.42. Over the past decade, Thyrocare Technologies' Pretax Margin % has ranged from 16.90 to 41.37. According to the industry distribution chart, Thyrocare Technologies ranks #11 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 5.5%.
Is Thyrocare Technologies' Pretax Margin % too high?
Thyrocare Technologies' current Pretax Margin % of 28.45% is near median its 10-year median of 29.42. Over the past 10 years, this metric has ranged from a low of 16.90 to a high of 41.37. Based on the distribution chart, Thyrocare Technologies ranks #11 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #11 out of 201 companies for Pretax Margin %. This places Thyrocare Technologies in the top 6% of its industry — outperforming the majority of peers. Historically, Thyrocare Technologies' own Pretax Margin % has ranged from 16.90 to 41.37 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Thyrocare Technologies and its competitors. Thyrocare Technologies's current Pretax Margin % is 28.45%, which is near median its own 10-year median of 29.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (BOM:539871) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹416.05, compared to a current price of ₹599.95 — trading 44.2% above its estimated fair value. The current Pretax Margin % is 28.45%, which is near median its 10-year median of 29.42. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Thyrocare Technologies (BOM:539871), the current Pretax Margin % is 28.45% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (BOM:539871) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹599.95 is trading 44.2% above its estimated GF Value™ of ₹416.05.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for BOM:539871:
Pretax Margin %: 28.45% (near median its 10-year median of 29.42)
GF Value™: ₹416.05 vs. price of ₹599.95 (44.2% above fair value)
No single metric tells the full story. See the BOM:539871 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for BOM:539871
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539871 has been successfully added to your 
